How can a health innovation translate into access and sustainable impact?
In Senegal’s Kédougou region, a pilot study is exploring how arpraziquantel (arPZQ), a new treatment for schistosomiasis among preschool-aged children, can be delivered through existing community health platforms. By examining practical questions around delivery, community acceptance and sustainability, the study is generating evidence that can inform wider access in Senegal and beyond.
Led by the University of Thiès in collaboration with Gaston Berger University and Senegal’s Ministry of Health and Social Action, the study is supported by the UNDP-led Access and Delivery Partnership (ADP), together with ADP partners TDR and PATH. Medicines for the study are supplied by the Izumi Foundation, while ADP is supported by the Government of Japan.
The work in Senegal is part of ADP’s broader contribution to expanding the rollout of arPZQ across Africa, including in Tanzania, and advancing equitable access for an estimated 50 million preschool-aged children, most of whom live in sub-Saharan Africa. It builds on longstanding collaboration between ADP and the GHIT Fund to help translate health innovation into access and sustainable impact.